AATD and Cancer Prevention Research

Cancer prevention is a major public health priority. Searches for lung, breast, and prostate cancer prevention attract millions of people each year. The Mark Egly Foundation's unique research angle asks whether restoring healthier AAT levels might influence inflammation and tissue damage pathways that appear in cancer biology.

This page is an education hub. It points you to disease pages in our catalog and to standard AATD resources. It does not claim that AAT treats or prevents cancer in clinical practice today.

Alpha-1 Antitrypsin Deficiency is a genetic condition that can cause lung disease (including emphysema and COPD) and liver disease. Testing and specialist care for severe AATD follow established clinical pathways. For a clear overview, start with:

• What is Alpha-1 Antitrypsin Deficiency
• Symptoms
• COPD
• Emphysema
• Genetic testing for COPD

People with AATD still need standard cancer screening appropriate to age and risk. AATD education does not replace oncology care.

Mark Egly's patent discusses neutrophil elastase, thrombospondin-1 (TSP1), and circulating AAT in the context of tumor development and spread. The filing names multiple cancers, including breast cancer subtypes, among conditions that may relate to low AAT or AATD.

Those claims remain a research hypothesis. They require independent clinical validation before they can change the standard of care.

These catalog pages target high interest prevention and disease keywords while keeping hypothesis labeling intact:

• Breast cancer and Alpha-1
• Lung cancer and Alpha-1
• Prostate cancer and Alpha-1

Related breast cancer subtype pages (metastatic, inflammatory, triple negative, and others) appear under the Cancer filter in Diseases.

Browse the full cancer category in the disease catalog. Examples include:

• Colorectal cancer
• Ovarian cancer
• Pancreatic cancer
• Melanoma and skin cancers

Each disease page offers layperson and professional audiences, with hypothesis labeling on every page.

1. Keep oncology screening and treatment plans with your cancer care team.
2. Learn established AATD facts on our education pages if lung or liver disease is part of your story.
3. Discuss AAT testing with a clinician when unexplained lung or liver disease, or a family history of AATD, raises the question.
4. Read Mark's patent overview for research context.
5. Support research funding if you want to advance independent study of these questions.

Review AATD diagnosis and testing and join Uniting Doctors. Keep patent cancer claims separated from guideline directed oncology.